Clinical Phenotyping In Sarcoidosis Using Cluster Analysis

Nancy W Lin

University of Colorado

Jaron Arbet

Colorado School of Public Health

Margaret M Mroz

National Jewish Health

Shu-Yi Liao

National Jewish Health

Clara I Restrepo

National Jewish Health

Annyce S Mayer

National Jewish Health

Li Li

National Jewish Health

Briana Q Barkes

National Jewish Health

Sarah Schrock

Colorado School of Public Health

Nabeel Hamzeh

The University of Iowa

Tasha E. Fingerlin

National Jewish Health

Nichole E Carlson

University of Colorado

Lisa Maier (✉ maierl@njhealth.org)

National Jewish Health <https://orcid.org/0000-0001-6872-1769>

Research

Keywords: Cluster Analysis, Disease Severity, Phenotypes, Pulmonary, Sarcoidosis

Posted Date: September 8th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-820722/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Respiratory Research on April 9th, 2022.

See the published version at <https://doi.org/10.1186/s12931-022-01993-z>.

Abstract

Background

Most phenotyping paradigms in sarcoidosis are based on expert opinion; however, no paradigm has been widely adopted because of the subjectivity in classification. We hypothesized that cluster analysis could be performed on common clinical variables to define more objective sarcoidosis phenotypes.

Methods

Model-based clustering was performed using the VarSelLCM R package to identify distinct phenotypes of sarcoidosis based on 29 clinical features. The Integrated Completed Likelihood (ICL) criteria were used to estimate number of clusters. To identify features associated with cluster membership, features were ranked based on variable importance scores from the VarSelLCM model, and additional univariate tests (Fisher's exact test and one-way ANOVA) were performed using q-values correcting for multiple testing. The Wasfi severity score was also compared between clusters.

Results

Cluster analysis resulted in 6 sarcoidosis phenotypes. Salient characteristics for each cluster are as follows: Phenotype 1) supranormal lung function and majority Scadding stage 2/3; phenotype 2) supranormal lung function and majority Scadding stage 0/1; phenotype 3) normal lung function and split Scadding stages between 0/1 and 2/3; phenotype 4) obstructive lung function and majority Scadding stage 2/3; phenotype 5) restrictive lung function and majority Scadding stage 2/3; phenotype 6) mixed obstructive and restrictive lung function and mostly Scadding stage 4. Clusters 4,5,6 were significantly more likely to have ever been on immunosuppressive treatment and had higher Wasfi disease severity scores.

Conclusions

Cluster analysis produced 6 sarcoidosis phenotypes that demonstrated non-severe and severe phenotypes. Phenotypes 1,2,3 have less lung function abnormalities, a lower percentage on immunosuppressive treatment and lower Wasfi severity scores. Phenotypes 4,5,6 were characterized by lung function abnormalities, more parenchymal abnormalities, an increased percentage on immunosuppressive treatment and higher Wasfi severity scores. These data support using cluster analysis as an objective and clinically useful way to phenotype sarcoidosis subjects.

Background

Sarcoidosis is a heterogeneous disease, affecting any organ and with variable natural history.^{1,2} Clinical phenotyping in complex diseases such as sarcoidosis can help define subpopulations with similar clinical/biological characteristics. Most importantly, phenotyping may differentiate disease course, identifying those with worse prognosis requiring long-term treatment and follow-up.³ Based on previous

studies, several characteristics portend worse prognosis in sarcoidosis, including race, Scadding stage, BMI, treatment status and lung function.^{4,5,6,7} However, transforming these characteristics into discrete and validated sarcoidosis phenotypes, especially ones with clinical implications for disease status and prognostication, has proved challenging.

Several phenotyping classifications have been proposed in sarcoidosis. Most rely on expert opinion even though this way may introduce bias, which can limit agreement between experts and consistency of application. An example of expert opinion based phenotyping was proposed in Wasfi et al., where a disease severity score was derived from subjective assessments by sarcoidosis experts.⁸ A benefit of the Wasfi score is the ease of obtaining inputs at one clinic visit to determine phenotype/severity. A limitation is that it has not been validated. Recently, cluster analysis has been used to determine phenotypes in many complex diseases. Cluster analysis employs multivariate algorithms to organize individuals into subgroups based on similarities.^{9,10} The clustering methodology is considered relatively unbiased since it employs objective statistical methods to group individuals rather than expert opinion; however, selection of input variables is still a subjective process. Schupp et al., Rubio-Rivas et al. and Lhote et al. have used cluster analysis to subgroup organ involvement in sarcoidosis.^{11,12,13} However, these phenotypes do not necessarily provide information on disease severity or prognosis and can be difficult to apply in a single clinic visit versus multiple visits over time.

We propose that cluster analysis can be used to identify clinical phenotypes of sarcoidosis including severe and non-severe forms of the disease. In this study we use this technique and include clinical variables that have influenced prognosis in previous studies. We will also associate resultant phenotypes with the Wasfi severity score to assess differences in disease severity between clusters. Some of the results of this study have been previously reported in the form of an abstract.¹⁴

Methods

Study Population

This was a cross-sectional, retrospective study on sarcoidosis cases seen in the Division of Occupational and Environmental Health Sciences at National Jewish Health (NJH) from 2008 to 2015. All subjects provided written informed consent to participate in this study. The study was approved by the NJH Institutional Review Board (HS 2458).

All sarcoidosis subjects met the American Thoracic Society/European Respiratory Society criteria for the diagnosis of sarcoidosis including tissue biopsy confirmation.² Medical charts were reviewed to ensure eligibility and extract clinical data. All subject information was collected at the reference enrollment date, defined as the time of spirometry and chest x-ray, except for treatment as noted below. If only spirometry was available, then that date was used for enrollment.

Gender, race, BMI and smoking status were collected at enrollment. The FVC% predicted (FVCpp), FEV1% predicted (FEV1pp), and FEV1/FVC ratio (%) were included in the analysis. For interpretation of spirometry data, we considered normal to be $\geq 80\%$ FEV1pp and FVCpp and $\geq 70\%$ FEV1/FVC as we did not have lower-limit-of-normal available for all participants.¹⁵ Scadding stages were determined by the interpreting radiologist from chest x-rays closest to enrollment. Biopsy dates were recorded if available and used to determine duration of disease and age at diagnosis.

Organ involvement was categorized based on the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis¹⁶ organ assessment tool. The likelihood of organ involvement was performed clinically by experts at the NJH clinic as a real-world method of determining organ involvement. Those presenting with traditional signs of Lofgren's syndrome were noted.

Treatment was defined as being on non-corticosteroid immunosuppressive therapy including methotrexate, azathioprine, mycophenolate mofetil, leflunomide, infliximab, and adalimumab. Hydroxychloroquine was not considered systemic treatment given its nonspecific indications. Treatment with corticosteroids, i.e. prednisone, was not included since some individuals are placed on steroids at diagnosis without a clinical indication. A dichotomous variable indicating the presence or absence of therapy up to five years after the enrollment date was included; this time frame was chosen to approximate those who were ever versus never treated.

Wasfi Severity Score

The sarcoidosis severity score, adapted from Wasfi et al.,⁸ was calculated for each individual using the following equation:

$$\text{Severity score} = 11.46 + 3.9(C) + 2.56(N) + 1.56(IS) - 0.051(\text{FVC\% predicted}) + 1.75(AA) - 0.054(\text{FEV1/FVC})$$

C = 1 for cardiac; N = 1 for neurological; IS = 1 if individual received non-corticosteroid immunosuppression within 30 days of enrollment date; AA = 1 for African American. Missing data was coded as a 0.

Statistical Analysis

All statistical analyses were performed using R (R Core Team, 2020).¹⁷ Model-based clustering was used to identify sarcoidosis phenotypes based on features shown in Table 1. Variations of the model included a single dichotomous extrapulmonary variable (absence or presence of extrapulmonary disease) versus individual organs. Clustering was performed using the VarSelLCM R package.¹⁸ We chose VarSelLCM given that it supports mixed types of features, missing values, and variable selection to identify important clustering features.¹⁹ The Integrated Completed Likelihood (ICL) criterion was used to estimate the number of clusters.²⁰ To identify features associated with cluster membership, variables were ranked based on the variable importance scores from the VarSelLCM model, and additional univariate tests (Fisher's exact test (FET) and one-way ANOVA) were performed. Pairwise comparisons were made

between clusters using 2-sample t-tests for quantitative features and logistic regression for categorical features (FET as appropriate). To account for multiple testing, the Benjamini-Hochberg method was used to calculate false-discovery-rate (FDR) adjusted p-values, hereby referred to as 'q-values.'²¹ Results with q-values < 0.05 were considered statistically significant.

Table 1
Characteristics of the Study Population

Characteristic	Missing: N(%)	N = 554 ¹
Gender	0 (0.0)	
Male		265 (47.8%)
Female		289 (52.2%)
Race	12 (2.2)	
White		443 (81.7%)
Black		90 (16.6%)
Asian		4 (0.7%)
American Indian		2 (0.4%)
Other		3 (0.6%)
Smoking Status	2 (0.4)	
Never smoker		367 (66.5%)
Ever smoker		185 (33.5%)
Lungs	0 (0.0)	534 (96.4%)
Cardiac	0 (0.0)	71 (12.8%)
Skin	0 (0.0)	68 (12.3%)
Eye	0 (0.0)	58 (10.5%)
Calcium/Vit D Metabolism	0 (0.0)	54 (9.7%)
Liver	0 (0.0)	40 (7.2%)
Extrathoracic lymph nodes	0 (0.0)	35 (6.3%)
Bone-Joint	0 (0.0)	19 (3.4%)
Spleen	0 (0.0)	19 (3.4%)
Lofgren's	0 (0.0)	17 (3.1%)
Other Organs	0 (0.0)	17 (3.1%)
Neuro	0 (0.0)	14 (2.5%)
ENT	0 (0.0)	12 (2.2%)
Kidney	0 (0.0)	9 (1.6%)

Characteristic	Missing: N(%)	N = 554 ¹
Muscle	0 (0.0)	7 (1.3%)
Parotid Salivary	0 (0.0)	5 (0.9%)
Bone Marrow	0 (0.0)	5 (0.9%)
Extrapulmonary Involvement	0 (0.0)	259 (46.8%)
Ever Treatment	104 (18.8)	310 (68.9%)
Scadding Stage	44 (7.9)	
0		102 (20.0%)
1		67 (13.1%)
2		183 (35.9%)
3		86 (16.9%)
4		72 (14.1%)
Number of organs involved	0 (0.0)	
0		10 (1.8%)
1		303 (54.7%)
2		149 (26.9%)
3		53 (9.6%)
4		24 (4.3%)
5		14 (2.5%)
6		1 (0.2%)
Mean number of organs	0 (0.0)	1.7 (1.0)
BMI	0 (0.0)	30.5 (6.8)
Age at Diagnosis	1 (0.2)	46.6 (10.9)
Duration of Disease	1 (0.2)	6.0 (7.1)
FEV1/FVC	0 (0.0)	74.9 (9.8)
FVCpp	0 (0.0)	86.7 (16.8)
FEV1pp	0 (0.0)	83.2 (19.4)
¹ Data presented: n (%); mean (SD)		

Results

Characteristics of study population

The characteristics of our study population, consisting of 554 individuals (Table 1), reflect a slight female majority and more White individuals, although there was a greater percentage of Black individuals than would be expected based on the racial breakdown of Colorado. The lungs were most commonly involved (96.4%) with Scadding stage 2 most prevalent. Next most frequently involved organs included cardiac (12.8%), skin (12.3%) and eye (10.5%). Most individuals had only one organ involved (54.7%). Most cases (68.9%) were treated with non-corticosteroid immunosuppression within 5 years of enrollment.

Cluster analysis defines six phenotypes

Six clusters were identified by model-based clustering. Based on the variable importance scores from the VarSelLCM model, the six variables most important for clustering in descending order were: FEV1pp, FVCpp, duration of disease, FEV1/FVC, Scadding stage and treatment status. The distributions of these variables are presented in Figs. 1–4. We evaluated differences across clusters in these variables as noted in Table 2. We describe specific abnormalities by cluster in Fig. 6a/6b.

Table 2
Differences in Clinical Characteristics across Phenotypes

Characteristic ^{1,2}	1, N = 103	2, N = 45	3, N = 111	4, N = 114	5, N = 88	6, N = 93	q- value ³
FEV1pp	104.4 (6.5) _E	105.7 (11.5) _E	91.8 (4.8) _D	80.3 (6.1) _C	71.2 (5.8) _B	53.2 (12.4) _A	< 0.001
FVCpp	104.3 (6.6) _E	107.9 (12.2) _E	87.5 (5.3) _C	89.5 (8.7) _D	72.2 (5.3) _B	66.3 (15.2) _A	< 0.001
FEV1/FVC	79.1 (4.8) _D	76.4 (5.5) _C	82.5 (4.0) _E	70.3 (5.4) _B	77.5 (6.2) _{C,D}	63.5 (13.6) _A	< 0.001
Duration of Disease (yrs)	2.0 (1.7) A	16.5 (9.9) _E	4.2 (3.8) B	6.3 (4.8) C	2.0 (1.8) A	11.1 (9.5) _D	< 0.001
Ever Treatment	39 (54.2%) A	16 (42.1%) A	52 (57.8%) A	74 (75.5%) B	54 (78.3%) B,C	75 (90.4%) C	< 0.001
Scadding Stage							< 0.001
0	19 (20.2%) B,C	22 (48.9%) D	32 (31.7%) C,D	18 (16.4%) B	7 (9.0%) A,B	4 (4.9%) A	
1	19 (20.2%) A	5 (11.1%) A	18 (17.8%) A	11 (10.0%) A	10 (12.8%) A	4 (4.9%) A	
2	39 (41.5%) B	8 (17.8%) A	33 (32.7%) A,B	35 (31.8%) A,B	47 (60.3%) C	21 (25.6%) A,B	
3	17 (18.1%) A	8 (17.8%) A	13 (12.9%) A	26 (23.6%) A	11 (14.1%) A	11 (13.4%) A	
4	0 (0.0%) A	2 (4.4%) A	5 (5.0%) A	20 (18.2%) B	3 (3.8%) A	42 (51.2%) C	
BMI	28.8 (5.2) _A	28.8 (6.0) _A	31.8 (7.4) _B	29.7 (6.1) _A	32.9 (7.4) _B	30.7 (7.3) _{A,B}	< 0.001
Age at Diagnosis	47.4 (11.0) _B	41.0 (11.6) _A	47.8 (10.5) _B	47.2 (11.2) _B	49.6 (9.7) _B	43.7 (10.7) _A	< 0.001

Characteristic ^{1,2}	1, N = 103	2, N = 45	3, N = 111	4, N = 114	5, N = 88	6, N = 93	q-value ³
Female	56 (54.4%) A,B	30 (66.7%) B	70 (63.1%) B	47 (41.2%) A	47 (53.4%) A,B	39 (41.9%) A	0.004
Lofgren's	6 (5.8%) A	3 (6.7%) A	6 (5.4%) A	0 (0.0%) A	1 (1.1%) A	1 (1.1%) A	0.016
Ever Smoker	31 (30.4%) A,B	19 (42.2%) A,B	30 (27.0%) A	31 (27.4%) A	30 (34.1%) A,B	44 (47.3%) B	0.024
Race							0.025
White	90 (90.0%) A	33 (75.0%) A	95 (86.4%) A	91 (79.8%) A	61 (72.6%) A	73 (81.1%) A	
Black	7 (7.0%) A	11 (25.0%) B	13 (11.8%) A,B	23 (20.2%) B	19 (22.6%) B	17 (18.9%) A,B	
Asian	1 (1.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	2 (2.4%)	0 (0.0%)	
American Indian	1 (1.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	
Other	1 (1.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	
Extrapulmonary Involvement	43 (41.7%)	21 (46.7%)	53 (47.7%)	62 (54.4%)	42 (47.7%)	38 (40.9%)	0.461
Cardiac	5 (4.9%)	6 (13.3%)	14 (12.6%)	23 (20.2%)	11 (12.5%)	12 (12.9%)	0.077
No. of organs	1.6 (1.0)	1.6 (1.1)	1.7 (1.1)	1.8 (1.0)	1.7 (1.0)	1.6 (1.0)	0.646

¹Data presented: n (%); mean (SD)

²Statistical tests performed: Fisher's exact test; Welch's one-way ANOVA. For pairwise comparisons, 2-sample t-tests and logistic regression were performed; groups sharing the same letter (A,B,C,D,E) do not have significantly different means or proportions (q>0.05).

³False discovery rate correction for multiple testing

For lung function (Fig. 1), mean FEV1pp and FVCpp were highest in cluster 1 (104.4 and 104.3 respectively) and cluster 2 (105.7 and 107.9). The highest mean FEV1/FVC ratio was present in cluster 3 (82.5). The clusters with lowest mean FEV1pp and FVCpp included cluster 5 (71.2 and 72.2) and cluster 6 (53.2 and 66.3). The clusters with significantly lower mean FEV1/FVC ratios included cluster 4 (70.3) and cluster 6 (63.5). Overall, cluster 6 had the lowest spirometry values out of all the clusters, although the

distribution of the interquartile range (IQR) was broad: FEV1pp (46–62), FVCpp (55–76), FEV1/FVC (55–72).

While each cluster included representation of all five Scadding stages (Fig. 2), differences in the percentages were apparent. Cluster 1 was predominantly composed of Scadding stage 2 (41.5%), while cluster 2 was predominated stage 0 (48.9%). Cluster 5 was mostly Scadding stage 2 (60.3%), while cluster 6 had a majority Scadding stage 4 (51.2%). Clusters 3 and 4 contained no one prominent Scadding stage.

Differences in duration of disease were noted (Fig. 3) with clusters 1 (2) and cluster 5 (2) having significantly shorter mean durations of disease. Cluster 2 (16.5) and cluster 6 (11.1) had the longest mean durations of disease; however, the IQR were broad for these clusters: cluster 2(8.4–21.9) and cluster 6(3.4–15.1). Clusters 3 (4.2) and 4 (6.3) had intermediate mean durations. Significantly more individuals were on treatment in clusters 4,5,6 compared to clusters 1,2,3 (Fig. 4).

Clinical characteristics differ between phenotypes

We evaluated the other variables entered in the cluster analysis to determine differences between clusters (Table 2, expanded table in online supplement Table E1). Figure 6a/6b represents specific abnormalities by cluster. In addition to the six variables mentioned above, BMI, age at diagnosis, gender, Lofgren's syndrome, smoking status and race differed significantly. Specifically, clusters 3 and 5 had higher average BMI than clusters 1,2,4, while clusters 2 and 3 had more females compared to more males in clusters 4 and 6. Cluster 6 contained more smokers compared to 3 and 4. More Black individuals were in clusters 2,4,5 versus cluster 1. Finally, individuals in clusters 2 and 6 were younger at diagnosis versus those in clusters 1,3,4 and 5. Interestingly, specific extrapulmonary organ involvement did not differ across clusters, however there was a trend toward significance for cardiac involvement. When the cluster analysis was rerun using "yes/no" for extrapulmonary involvement, there were still no differences across clusters; additionally, analysis yielded the same results with the same six clusters.

Wasfi score association with phenotypes

We evaluated the association of the Wasfi severity score with each of our clusters. The mean Wasfi score differed significantly across the six clusters ($p < 0.001$, Fig. 5), with clusters 4,5,6 (mean scores of 5, 5.2 and 6.5 respectively) significantly higher than cluster 1,2,3 (mean scores 2.6, 3.2 and 3.8).

Phenotypes of sarcoidosis disease severity

Based on our cluster analyses, and their associations with clinical variables and Wasfi score analyses, we categorized the clusters based on disease severity and other disease findings. Overall, it appears that the clusters reflect non-severe (clusters 1,2,3) and severe pulmonary disease manifestations (clusters 4,5,6) (Fig. 6a/6b). Specifically, individuals in clusters 4,5,6 had at least one lung function parameter lower than normal and required more treatment versus those in clusters 1,2,3. The individuals in clusters 4,5,6 also had unique patterns of lung function abnormalities, specifically obstructive, restrictive and mixed patterns, respectively. Scadding stage was less distinctly distributed between the severe and non-severe

clusters, although the severe phenotypes had less stage 0/1 disease and cluster 6 had more stage 4 disease, consistent with a fibrotic phenotype. Interestingly, severe clusters 4 and 6 had more males than non-severe clusters 2 and 3. The rest of the variables did not demonstrate a clear distinction between severe and non-severe clusters. Based on lung function and radiological differences, we named the clusters as noted in Figs. 6a/6b.

Discussion

There is a pressing need for sarcoidosis phenotypes that can identify those with or at risk for severe disease and to classify them for research studies. We used cluster analysis on clinical characteristics to define sarcoidosis phenotypes and found that common clinical variables contributed most to the clustering, including spirometry, disease duration, Scadding stage and immunosuppressive treatment. Unexpectedly, we defined six distinct pulmonary phenotypes that included severe and non-severe disease manifestations but did not differ in extrapulmonary organ involvement. The three non-severe phenotypes were classified as supranormal lung function with parenchymal disease, supranormal lung function with no parenchymal disease and normal lung function. The three severe phenotypes included obstructive physiology with parenchymal disease, restrictive physiology with non-fibrotic parenchymal disease and mixed physiology with fibrotic lung disease. Interestingly, male gender was predominant in two of the more severe clusters while females predominated the less severe clusters. Unsurprisingly, Black individuals made up a greater proportion in two of the severe clusters, and a similar proportion in one of the less severe clusters. Finally, we validated our cluster phenotypes with a previously determined assessment of disease severity developed by our group, the Wasfi score, and found that our less severe clusters had lower scores, while the more severe clusters had higher scores.

Our clusters describe pulmonary disease phenotypes despite the inclusion of other organ involvement. Our unique phenotypes suggest subgroups of pulmonary sarcoidosis based on different lung function and radiographic abnormalities. Our severe phenotypes clusters 4,5,6 had lower lung function that was obstructive, restrictive and mixed respectively and were associated with different Scadding stages. Various lung function abnormalities have been implicated with worse outcomes in sarcoidosis, specifically FVC < 80%, FEV1 < 50% and a vital capacity less than 1.5 liters.^{5,22,23,24} Previous studies have shown limited correlation between initial Scadding stage and subsequent clinical recovery or lung function^{4,25,26,24} except for Scadding Stage 0 and 4, which have been associated with good and poor prognosis respectively. Indeed, we identified more Scadding stage 4 in our cluster with the worst lung function and Scadding stage 0/1 in our cluster with supranormal lung function. However, Scadding stages 2/3 were represented in both severe and non-severe clusters, which supports that Scadding stage is a poor disease predictor except at the extremes. This is not surprising as other studies have found that extremes in Scadding stage, and not stages 2/3, tend to be more predictive of disease course/severity; this is likely due to the vast spectrum of disease abnormalities represented by stage 2/3. The need for treatment is often associated with chronic respiratory impairment.^{22,27} Those who are initially treated are more likely to require treatment at follow-up and relapse with treatment cessation.^{7,25} We find a clear

association with treatment and severe and non-severe clusters with more individuals in the severe groups on non-corticosteroid immunosuppressive treatment. Individuals who were diagnosed at earlier ages had the longest durations of disease, which did not correlate with disease severity. Clusters that share a similar duration of disease allow identification of distinct phenotypes at a similar point in time without having longitudinal data. For instance, clusters 1 and 5 share a similar short disease duration (average 2 years), but it is obvious these are two distinct phenotypes with cluster 1 exhibiting less severe disease than cluster 5. To determine how the clusters change over time would require longitudinal data, which we did not include; it is possible that individuals may move from one phenotype to another at different time points.

While some of our findings support prior studies, others were unexpected. For example, males were the majority of our severe clusters 4 and 6, while females were the majority in the less severe clusters 2 and 3. These findings are somewhat at odds with prior studies where women, especially Black women, have higher mortality^{28,29} and more severe organ involvement.^{30,31} However, these findings may support studies suggesting that males have a more chronic course than females.²³ Surprisingly, our non-severe cluster 2 had a greater frequency of Black individuals than the other non-severe clusters although severe clusters 4 and 5 also had more Black individuals. There is significant literature supporting that Black individuals have more severe disease requiring treatment and higher associated mortality.^{4,7,32,28,29} Most of our participants in this study were White, which may have impacted the results, although they may also suggest that severe sarcoidosis affects all races. It is well documented that there is a decreased prevalence of sarcoidosis among smokers.^{33,34,35,36} However, we found that our most severe cluster 6 had the highest percent smokers, suggesting that disease severity may be worse for smokers. This is seen in other pulmonary granulomatous diseases such as chronic beryllium disease and hypersensitivity pneumonitis, where smokers have worse pulmonary function and require more treatment compared to never smokers despite having a lower prevalence of disease.^{37,38}

We compared our phenotypes to another phenotyping method developed by our group; the Wasfi severity score gives a numerical severity index developed to codify expert opinion.⁸ Our three severe disease clusters were associated with higher Wasfi severity scores. This was not surprising as the features clustered in our severe phenotypes, abnormal spirometry and treatment, are part of the Wasfi score. Unlike the Wasfi score, non-pulmonary organ involvement, including cardiac and neurological, did not contribute to our clusters/phenotypes. Our treatment variable timeframe was different than that used in the Wasfi severity score because we wanted to approximate ever treatment in our cohort using a 5-year timeframe instead of the 30-day timeframe used in Wasfi; however, we found that the Wasfi 30-day treatment variable was highly correlated with our 5-year treatment variable. Other studies have used cluster analyses to define phenotypes in sarcoidosis.^{12,13,39,40} However, in contrast to our study, they used organ specific variables to produce organ-based phenotypes. Unexpectedly in our study, extrapulmonary organ variables did not contribute to the clustering of our phenotypes; while cardiac involvement trended toward being significantly different between clusters, we did not see more cardiac involvement in our severe phenotypes as we anticipated. This might be due to low extrapulmonary organ frequencies in our

cohort, although performing cluster analysis using only the presence/absence of extrapulmonary disease did not affect our results. Additionally, Schupp et al. included similarly low extrapulmonary organ frequencies in a large European cohort to develop organ-based phenotypes.³⁹ Our results may suggest that extrapulmonary organ involvement is not a predominant phenotype when clinically relevant pulmonary variables are included; pulmonary involvement is overwhelmingly the most commonly involved organ in sarcoidosis and results in significant morbidity and mortality.⁴¹ A study by Rodrigues et al., used factor analysis with clinical input variables similar to those used in our study to analyze a Brazilian cohort and found four phenotypes.⁴² Similar to our results, they found a phenotype characterized by fibrosis/Scadding stage 4 and decreased lung function parameters as well as one marked by airflow obstruction. Despite the differences in our statistical methods, the similarities in our resultant phenotypes do suggest consistency of results as well as demonstration of the importance of including clinically relevant variables.

While we are a major sarcoidosis referral center, we often see more complicated cases, including severe pulmonary and extrapulmonary disease; this may have biased our cohort towards more severe disease. While this could have impacted extrapulmonary disease severity, our rates of other organ involvement were similar to other studies.³⁹ Our study emphasizes the need for inclusion of clinically relevant measures of extrapulmonary disease severity, like arrhythmias or ejection fraction for cardiac disease, if the goal is to evaluate other organ specific or overall severe disease. We did not have patient reported outcomes or symptoms, which could provide information missed by objective measurements in a phenotyping paradigm designed to assess disease course and therapeutic intervention; organ specific phenotypes may or may not be helpful for these applications. We did not have longitudinal data to test the stability of our clusters over time, although we were able to infer some longitudinal information based on duration of disease as described above; additionally, previous studies have noted stability in FVC, FEV1 and Scadding stage over a two-year period suggesting that many of our clusters may remain the same over this time frame.²⁶ Finally, given the inherent uncertainty in statistical techniques we cannot say that there are definitively only six sarcoidosis clusters, which is an issue that applies to all forms of cluster analyses.

Conclusion

In conclusion, this study is novel in that it uses the objective method of cluster analyses to clinically phenotype sarcoidosis patients with easily obtained clinical characteristics beyond organ involvement. It demonstrates the importance of clinical variables to define clinically relevant phenotypes and suggests that inclusion of longitudinal data may add to the model, which is a plan for future directions. Furthermore, these pulmonary phenotypes were further categorized into non-severe and severe phenotypes, and the methods of this study suggest an approach for other organ specific phenotyping. Finally, these phenotypes have the potential to help identify subgroups in this heterogeneous disease that may have implications in follow-up, prognosis and possibly interventions.

Abbreviations

Body Mass Index (BMI)

False-discovery-rate (FDR)

Fisher's exact test (FET)

Forced expiratory volume in one second percent predicted (FEV1pp)

Forced vital capacity percent predicted (FVCpp)

Forced expiratory volume in one second / Forced vital capacity (FEV1/FVC)

Integrated Completed Likelihood (ICL)

Interquartile range (IQR)

National Jewish Health (NJH)

Declarations

Ethics approval and consent to participate

All subjects provided written informed consent to participate in this study. The study was approved by the NJH Institutional Review Board (HS 2458).

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

1. 1R01 HL142049-03

2. 5R01HL114587-06

Authors' contributions

Nancy W. Lin: Investigation, Methodology, Data curation, Writing – Original Draft **Jaron Arbet:** Methodology, Software, Formal Analysis, Visualization, Writing – Original Draft **Margaret M. Mroz:** Conceptualization, Methodology, Validation, Writing – Review & Editing **Shu-Yi Liao:** Conceptualization, Methodology, Writing – Review & Editing **Clara I. Restrepo:** Conceptualization, Writing – Review & Editing **Annyce S. Mayer:** Conceptualization, Writing – Review & Editing, Visualization **Li Li:** Visualization, Writing – Review & Editing **Briana Q. Barks:** Data curation, Writing – Review & Editing **Sara Schrock:** Data Curation, Investigation **Nabeel Hamzeh:** Data Curation, Resources, Writing – Review & Editing **Tasha E. Fingerlin:** Methodology, Writing – Review & Editing, Funding Acquisition **Nichole E. Carlson:** Methodology, Writing – Review & Editing, Funding Acquisition **Lisa A Maier:** Conceptualization, Methodology, Writing – Review & Editing, Supervision, Project Administration, Funding Acquisition

NL, JA, MM, SL, CR, AM, LL, BB, SS, NH, TF, NC, LM contributed substantially to the study design, data analysis and interpretation, and the writing of the manuscript.

Acknowledgements

Not applicable.

References

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ER. *Am J Respir Crit Care Med.* 1999;160(2):736–55. doi:10.1164/ajrccm.160.2.ats4-99.
2. Crouser ED, Maier LA, Wilson KC, Bonham CA, Morgenthau AS, Patterson KC, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med.* 2020;201(8):e26–51. doi:10.1164/rccm.202002-0251ST.
3. Pereira CAC, Dornfeld MC, Baughman R, Judson MA. Clinical phenotypes in sarcoidosis. *Curr Opin Pulm Med.* 2014;20(5):496–502. doi:10.1097/MCP.0000000000000077.
4. Israel HL, Karlin P, Menduke H, DeLisser OG. Factors affecting outcome of sarcoidosis. Influence of race, extrathoracic involvement, and initial radiologic lung lesions. *Ann N Y Acad Sci.* 1986;465(1 Tenth Interna):609–18. doi:10.1111/j.1749-6632.1986.tb18537.x.
5. Viskum K, Vestbo J. Vital prognosis in intrathoracic sarcoidosis with special reference to pulmonary function and radiological stage. *Eur Respir J.* 1993;6(3):349–53.
6. Cozier YC, Coogan PF, Govender P, Berman JS, Palmer JR, Rosenberg L. Obesity and weight gain in relation to incidence of sarcoidosis in US black women: Data from the Black Women's Health Study. *Chest.* 2015;147(4):1086–93. doi:10.1378/chest.14-1099.
7. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis: The relationship of relapse to corticosteroid therapy. *Chest.* 1997;111(3):623–31. doi:10.1378/chest.111.3.623.

8. Wasfi YS, Rose CS, Murphy JR, Silveira LJ, Grutters JC, Inoue Y, et al. A new tool to assess sarcoidosis severity. *Chest*. 2006;129(5):1234–45. doi:10.1378/chest.129.5.1234.
9. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. *Am J Respir Crit Care Med*. 2008;178(3):218–24. doi:10.1164/rccm.200711-1754OC.
10. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. *Am J Respir Crit Care Med*. 2010;181(4):315–23. doi:10.1164/rccm.200906-0896OC.
11. Schupp JC, Freitag-Wolf S, Bargagli E, Mihailović-Vučinić V, Rottoli P, Grubanovic A, et al. Phenotypes of organ involvement in sarcoidosis. *Eur Respir J*. 2018;51(1):1–11. doi:10.1183/13993003.00991-2017.
12. Rubio-Rivas M, Corbella X. Clinical phenotypes and prediction of chronicity in sarcoidosis using cluster analysis in a prospective cohort of 694 patients. *Eur J Intern Med*. 2020;77(April):59–65. doi:10.1016/j.ejim.2020.04.024.
13. Lhote R, Annesi-Maesano I, Nunes H, Launay D, Borie R, Sacré K, et al. Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multiethnic, multicenter cohort. *Eur Respir J*. Published online 2020:2001160. doi:10.1183/13993003.01160-2020.
14. Lin N, Arbet J, Liao S, Mroz M, Restrepo C, Barkes B, Li L, Fingerlin T, Carlson N, Maier L. Comparing Cluster Analysis to Expert Opinion in Phenotyping Sarcoidosis. American Thoracic Society Conference. Published online 2021.
15. Culver BH, Graham BL, Coates AL, Wanger J, Berry CE, Clarke PK, et al. Recommendations for a standardized pulmonary function report. An official American Thoracic Society technical statement. *Am J Respir Crit Care Med*. 2017;196(11):1463–72. doi:10.1164/rccm.201710-1981ST.
16. Moller DR, Koth LL, Maier LA, Morris A, Drake W, Rossman M, et al. Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) Study. *Sarcoidosis Protocol*. *Ann Am Thorac Soc*. 2015;12(10):1561–71. doi:10.1513/AnnalsATS.201503-172OT.
17. R Core Team. (2020). R: A language and environment for statistical computing. Published online 2020.
18. Marbac M, Sedki M. VarSelLCM. An R/C ++ package for variable selection in model-based clustering of mixed-data with missing values. *Bioinformatics*. 2019;35(7):1255–7. doi:10.1093/bioinformatics/bty786.
19. Fop M, Murphy TB. Variable selection methods for model-based clustering. *Stat Surv*. 2018;12:18–65. doi:10.1214/18-SS119.
20. Biernacki C, Celeux G, Govaert G. Assessing a mixture model for clustering with the integrated completed likelihood. *IEEE Trans Pattern Anal Mach Intell*. 2000;22(7):719–25. doi:10.1109/34.865189.
21. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J R Stat Soc Ser B*. 1995;57(1):289–300. doi:10.1111/j.2517-6161.1995.tb02031.x.

22. Baughman RP, Lower EE. Features of sarcoidosis associated with chronic disease. *Sarcoidosis Vasc Diffus Lung Dis*. 2014;31(4):275–81.
23. Mañá J, Salazar A, Pujol R, Manresa F. Are the pulmonary function tests and the markers of activity helpful to establish the prognosis of sarcoidosis. *Respiration*. 1996;63(5):298–303. doi:10.1159/000196564.
24. Baughman RP, Winget DB, Bowen EH, Lower EE. Predicting respiratory failure in sarcoidosis patients. *Sarcoidosis Vasc Diffus lung Dis Off J WASOG*. 1997;14(2):154–8. <http://www.ncbi.nlm.nih.gov/pubmed/9306506>.
25. Baughman RP, Judson MA, Teirstein A, Yeager H, Rossman M, Knatterud GL, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. *QJM - Mon J Assoc Physicians*. 2006;99(5):307–15. doi:10.1093/qjmed/hcl038.
26. Judson MA, Baughman RP, Thompson BW, Teirstein AS, Terrin ML, Rossman MD, et al. Two year prognosis of sarcoidosis: The ACCESS experience. *Sarcoidosis Vasc Diffus Lung Dis*. 2003;20(3):204–11.
27. Ungprasert P, Crowson CS, Carmona EM, Matteson EL. Outcome of pulmonary sarcoidosis: A population-based study 1976–2013. *Sarcoidosis Vasc Diffus Lung Dis*. 2018;35(2):123–8. doi:10.36141/svdld.v35i2.6356.
28. Swigris JJ, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger D, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. *Am J Respir Crit Care Med*. 2011;183(11):1524–30. doi:10.1164/rccm.201010-1679OC.
29. Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. *Chest*. 2015;147(2):438–49. doi:10.1378/chest.14-1120.
30. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. *Am J Respir Crit Care Med*. Published online 2001. doi:10.1164/ajrccm.164.10.2104046.
31. Gerke AK, Judson MA, Cozier YC, Culver DA, Koth LL. Disease burden and variability in sarcoidosis. *Ann Am Thorac Soc*. 2017;14:421–8. doi:10.1513/AnnalsATS.201707-564OT.
32. Sones M, Israel HL. Course and prognosis of sarcoidosis. *Am J Med*. 1960;29(1):84–93. doi:10.1016/0002-9343(60)90009-7.
33. Ungprasert P, Crowson CS, Matteson EL. Smoking, obesity and risk of sarcoidosis: A population-based nested case-control study. *Respir Med*. 2016;120(3):87–90. doi:10.1016/j.rmed.2016.10.003.
34. Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. A case control etiologic study of sarcoidosis: Environmental and occupational risk factors. *Am J Respir Crit Care Med*. 2004;170(12):1324–30. doi:10.1164/rccm.200402-249OC.
35. Valeyre D, Soler P, Clerici C, Pré J, Battesti JP, Georges R, et al. Smoking and pulmonary sarcoidosis: Effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease. *Thorax*. 1988;43(7):516–24. doi:10.1136/thx.43.7.516.

36. Harf RA, Ethevenaux C, Gleize J, Perrin-Fayolle M, Guerin JC, Ollagnier C. Reduced prevalence of smokers in sarcoidosis. Results of a case-control study. *Ann N Y Acad Sci.* 1986;465(1):625–31. doi:10.1111/j.1749-6632.1986.tb18539.x.
37. Mroz MM, Maier LA, Strand M, Silviera L, Newman LS. Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease. *Am J Ind Med.* 2009;52(10):762–73. doi:10.1002/ajim.20736.
38. Blanchet MR, Israël-Assayag E, Cormier Y. Inhibitory effect of nicotine on experimental hypersensitivity pneumonitis in vivo and in vitro. *Am J Respir Crit Care Med.* 2004;169(8):903–9. doi:10.1164/rccm.200210-1154oc.
39. Schupp JC, Freitag-Wolf S, Bargagli E, Mihailović-Vučinić V, Rottoli P, Grubanovic A, et al. Phenotypes of organ involvement in sarcoidosis. *Eur Respir J.* 2018;51(1):1–11. doi:10.1183/13993003.00991-2017.
40. Papiris SA, Georgakopoulos A, Papaioannou AI, Pianou N, Kallergi M, Kelekis NL, et al. Emerging phenotypes of sarcoidosis based on 18F-FDG PET/CT: a hierarchical cluster analysis. *Expert Rev Respir Med.* 2020;14(2):229–38. doi:10.1080/17476348.2020.1684902.
41. Nardi A, Brillet PY, Letoumelin P, Girard F, Brauner M, Uzunhan Y, et al. Stage IV sarcoidosis: Comparison of survival with the general population and causes of death. *Eur Respir J.* 2011;38(6):1368–73. doi:10.1183/09031936.00187410.
42. Rodrigues SCS, Rocha NAS, Lima MS, Arakaki JSO, Coletta ENA, Ferreira RG, et al. Factor analysis of sarcoidosis phenotypes at two referral centers in Brazil. *Sarcoidosis Vasc Diffus Lung Dis.* 2011;28(1):34–43.

Figures

Figure 1

Comparison of lung function parameters among clusters. For each cluster, median and IQR are shown by boxplots and means are shown by x in the center of boxplots for a) FEV1pp b) FVCpp and c) FEV1/FVC. Potential outliers are indicated by distinct points.

Figure 2

Distribution of Scadding stages 0-4 in each cluster. The representation of each Scadding stage in a cluster by percent is shown for all six clusters.

Figure 3

Comparison of duration of disease in years among clusters. For each cluster, median and IQR are shown by boxplots and means are shown by x in the center of boxplots. Potential outliers are indicated by distinct points.

Figure 4

Distribution of cases treated with non-corticosteroid immunosuppression in each cluster. Percent of individuals who ever received immunosuppressive treatment are represented in dark gray, while percent of individual who have never received immunosuppressive treatment are in light gray.

Figure 5

Wasfi Scores by Cluster. For each cluster, median and IQR are shown by boxplots and means are shown by x in the center of boxplots. Higher scores indicate greater severity.

Clusters with Less Severe Disease Features					
Cluster #	Cluster Name	Significant Characteristics (q<0.05)	Severe Disease Features	Additional Significant Pairwise Comparisons (q<0.05)	Mean Wasfi Score (SD)
1	Supranormal Lung Function with Parenchymal Disease	<ul style="list-style-type: none"> ↑ FEV1pp, FVCpp • Mostly Scadding stage 2/3 • Short Duration of Disease ↓ On Treatment 		<ul style="list-style-type: none"> • lower BMI vs clusters 3,5 • less black vs clusters 2,4,5 • older age at diagnosis vs clusters 2,6 	2.6(1.6)
2	Supranormal Lung Function with no Parenchymal Disease	<ul style="list-style-type: none"> ↑ FEV1pp, FVCpp • Mostly Scadding Stage 0/1 • Long Duration of Disease ↓ On Treatment 		<ul style="list-style-type: none"> • lower BMI vs clusters 3,5 • more female vs clusters 4,6 • more Black vs clusters 1 • younger age at diagnosis vs clusters 1,3,4,5 	3.2(2.2)
3	Normal Lung Function	<ul style="list-style-type: none"> • Normal Lung Function • Split between Scadding Stage 0/1 and 2/3 • Intermediate Duration of Disease ↓ On Treatment 		<ul style="list-style-type: none"> • higher BMI vs clusters 1,2,4 • more female vs clusters 4,6 • less smokers vs cluster 6 • older age at diagnosis vs clusters 2,6 	3.8(2.0)
4	Obstructive Physiology with Parenchymal Disease	<ul style="list-style-type: none"> ↓ FEV1/FVC • Mostly Scadding Stage 2/3 • Intermediate Duration of Disease ↑ On Treatment 		<ul style="list-style-type: none"> • lower BMI vs clusters 3,5 • more male vs clusters 2,3 • less smokers vs cluster 6 • more Black vs cluster 1 • older age at diagnosis vs cluster 2,6 	5(2.2)
5	Restrictive Physiology with Non-Fibrotic Parenchymal Disease	<ul style="list-style-type: none"> ↓ FEV1pp, FVCpp • Mostly Scadding stage 2/3 • Short Duration of disease ↑ On Treatment 		<ul style="list-style-type: none"> • higher BMI vs clusters 1,2,4 • more Black vs clusters 1 • older age at diagnosis vs clusters 2,6 	5.2(1.8)
6	Mixed Physiology with Fibrotic Lung Disease	<ul style="list-style-type: none"> ↓ FEV1pp, FVCpp, FEV1/FVC • Mostly Scadding Stage 4 • Long Duration of disease ↑ On Treatment 		<ul style="list-style-type: none"> • more male vs clusters 2,3 • more smokers vs clusters 3,4 • younger age at diagnosis vs clusters 1,3,4,5 	6.5(1.9)

Figure 6

a.Cluster Descriptions by Less Severe Disease Features / Figure 6b. Cluster Descriptions by More Severe Disease Features. The first column describes the cluster number, and the second column describes the cluster name. The third column includes significant differences in the six most important variables for clustering; arrows indicate a significant difference between less severe clusters (1,2,3) and more severe clusters (4,5,6) (q<0.05). The fourth column shows which severe disease features are present in clusters;

shading in the Venn diagram indicates that the majority of individuals had that particular disease feature; partial shading indicates half of individuals had the disease feature. The fifth column describes significant pairwise differences between clusters ($q < 0.05$). Finally, the sixth column describes the mean Wasfi score for that cluster.